(1)生物活性天然产物的分子优化、虚拟筛选和体内外评价;
(2)药物合成新方法和新工艺研究;
(3)基于活性药物分子开展药物新剂型和新功能研究。
(1)生物活性天然产物的分子优化、虚拟筛选和体内外评价;
(2)药物合成新方法和新工艺研究;
(3)基于活性药物分子开展药物新剂型和新功能研究。
(一)学习和工作经历:
1999.9-2003.7 武汉工程大学化工与制药学院制药工程专业,学士;
2004.9-2009.7 华南理工大学化学与化工学院化学工程专业,博士;
2009.7-至今 中国药科大学制药与环境工程系任教;
2015.3-2016.3 美国加州大学洛杉矶分校(UCLA)化学与生物化学系Michael E. Jung教授实验室,国家公派访问学者。
(二)教学工作:
1、主讲本科生课程《制药工程制图》、研究生课程《高等合成技术》和《高等制药分离工程》。
2、主编教材《制药工程制图》和《制药工程制图习题集》(第三版,化学工业出版社,2021),参编教材8本。
3、主持校级教改课题:研究生精品课程-《高等合成技术》(2022)、研究生专业学位课程改革项目-《高等合成技术》(2022)、基于“培养解决复杂问题能力”的教学内容和方法改革研究(2021)。
4、作为指导教师荣获江苏省第五届大学生生物医学工程创新设计竞赛三等奖(2024)、“东富龙-国药工程杯”第十届全国大学生制药工程设计竞赛三等奖(2022),个人荣获中国药科大学微课教学比赛三等奖(2022)和“澳天力奖教金”一等奖(2018)。
5、担任本科生导师3次,指导大学生创新创业计划项目11次。
(三)社会兼职:
担任European Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters等学术期刊审稿人。
(1)生物活性天然产物的分子优化、虚拟筛选和体内外评价;
(2)药物合成新方法和新工艺研究;
(3)基于活性药物分子开展药物新剂型和新功能研究。
主持重大新药创制科技重大专项课题(2019ZX09201001-004-001)
主持江苏省自然科学基金面上项目(BK20201329)
主持中央高校基本科研业务费专项资金重点项目(2632018ZD01)
主持江苏省自然科学基金青年基金项目(BK20130648)
主持天然药物活性组分与药效国家重点实验室优秀青年学者基金项目(JKGQ201112)
主持中央高校基本科研业务费专项资金青年项目(JKQ2009007)
主持企业横向开发课题数项
参与国家重点研发计划项目(2017YFD0400402)
参与国家自然科学基金面上项目(81573313)
参与国家自然科学基金面上项目(20976060)
主持和参与企业委托横向项目数项
近来发表的代表性科研论文如下:
Haoyi Yang1, Dongyu Zhang1, Ziyang Yuan1, Haishi Qiao, Zhuolu Xia, Feng Cao*, Yuanyuan Lu*, Feng Jiang*. Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent. European Journal of Medicinal Chemistry, 2024, 267, 116205.
Jinhui Lu1, Xiaomeng Zhu1, Meng Zhang1, Xunchan Jiang, Wei Guo*, Feng Jiang*, Feng Cao*. In vitro and in vivo assessment of structural integrity for HPCD complex@Liposome nanocomposites from ocular surface to the posterior segment of the eye. Carbohydrate Polymers, 2023, 315, 120960.
Chunhua Zhang, Qifan Ding, Zhuolu Xia, Hengyu Wang, Feng Jiang* and Yuanyuan Lu*. Novel Chalcone-Phenazine Hybrids Induced Ferroptosis in U87-MG Cells through Activating Ferritinophagy. Chemistry & Biodiversity, 2023, 20, e202201117.
Yue Yang1, Yuanyuan Lu1, Chunhua Zhang1, Qianqian Guo, Wenzhou Zhang, Ting Wang, Zhuolu Xia, Jing Liu, Xiangyu Cheng, Tao Xi*, Feng Jiang*, Lufeng Zheng*. Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis. Cellular and Molecular Life Sciences, 2022, 79: 360.
Haojie Lu‡, Jing Liu‡, Meizhe Yu, Peili Li, Ruobing Huang, Wenzhen Wu, Zunhan Hu, Yuhong Xiao,* Feng Jiang* and Xiaodong Xing*. Photothermal-enhanced antibacterial and antioxidant hydrogel dressings based on catechol-modified chitosan-derived carbonized polymer dots for effective treatment of wound infection. Biomaterials Science, 2022, 10, 2692-2705.
Yuanyuan Song#, Ziqi Wang#, Yijing Long, Yang Mao, Feng Jiang*, Yuanyuan Lu*. 2-Alkyl-anthraquinones inhibit Candida albicans biofilm via inhibiting the formation of matrix and hyphae. Research in Microbiologoy,, 2022, 173, 103955.
Yucheng Zhong1, Jing Liu1, Xiangyu Cheng, Hao Zhang, Chunhua Zhang, Zhuolu Xia, Zhongxi Wu, Lu Zhang, Yuting Zheng, Zhanyu Gao, Zhidong Jiang, Zhixiang Wang,Dechun Huang, Yuanyuan Lu*, Feng Jiang*. Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors. Bioorganic Chemistry, 2021, 109, 104736.
Jing Liu+, Fei Ji+, Zhuolu Xia, Chunhua Zhang, Changshun Zhao, Yanfei Li, Xiang Zhou, Dechun Huang, Wei Chen*, Feng Jiang*. Multifunctional nanoaggregates composed of active CPUL1 and a triphenylphosphine derivative for mitochondria-targeted drug delivery and cell imaging. ChemMedChem, 2021, 16, 1-6.
Dechun Huang, Zhonglin Zhu, Qiming Wang, Beichen Qin, Lin Dai, Feng Jiang, Wei Liu*, Hongliang Qian*. Prediction model, experimental optimization, and verification for yield of high-pressure crystallization: a case study of citric acid. Separation Science and Technology, 2020,55(1): 135-143.
Jianming Liao, Linlin Wang, Zhongxi Wu, Zhixiang Wang, Jun Chen, Yucheng Zhong, Feng Jiang*, Yuanyuan Lu*. Identification of phenazine analogue as a novel scaffold for thioredoxin reductase I inhibitors against HepG2 cancer cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34(1): 1158-1163.
Meichen Zhang, Shuhui Gu, Guangpan Liu, Chencheng Li, Hanmei Xu*, Zhongxi Wu, Boping Ye, Yuanyuan Lu, Dechun Huang, Zhixiang Wang, Feng Jiang*. Facile synthesis and cytotoxicity of phenazine-chromene hybrid molecules derived from phenazine natural product. Combinatorial Chemistry & High Throughput Screening, 2019, 22(1): 35-40.
Jing Zhang, Qiming Wang, Zhonglin Zhu, Hongliang Qian, Feng Jiang, Zhixiang Wang, Wei Liu*, Dechun Huang*. Micronization of gefitinib using solution‐enhanced dispersion by supercritical CO2. Chemical Engineering & Technology, 2019, 42(2): 388-396.
Hongliang Qian, Lin Dai, Feng Jiang, Yiqiang Shi, Zhixiang Wang, Wei Liu*, Dechun Huang*, Wei Chen. Quantitative design of seed load based on model identification of nucleation and crystal growth stages without transmittance data. Powder Technology. 2018, 335, 11-17.
Yuanyuan Lu, Yuru Yan, Linlin Wang, Xiaobing Wang, Jing Gao, Tao Xi, Zhixiang Wang, Feng Jiang*. Design, facile synthesis and biological evaluations of novel pyrano[3,2-a]phenazine hybrid molecules as antitumor agents. European Journal of Medicinal Chemistry. 2017, 127, 928-943.
Yuanyuan Lu*, Linlin Wang, Xiaobing Wang, Tao Xi, Jianmin Liao, Zhixiang Wang, Feng Jiang*. Design, combinatorial synthesis and biological evaluations of novel 3-amino-1′-((1-aryl-1H-1,2,3-triazol-5-yl)methyl)-2′-oxospiro[benzo[a] pyrano[2,3-c]phenazine-1,3′-indoline]-2-carbonitrile antitumor hybrid molecules. European Journal of Medicinal Chemistry. 2017, 135, 125-141.
授权发明专利如下:
江峰, 王荣, 刘静等. 二硫键修饰的纳米聚集体及其制备方法和应用. 中国发明专利2022111500513.
江峰, 夏卓璐, 张东宇等. 吡喃并喹啉衍生物及其制备方法和应用. 中国发明专利2022106500674.
江峰, 王荣, 陆园园等. 一种查尔酮吩嗪杂化分子及其应用. 中国发明专利2022106290021.
江峰, 刘静, 黄德春等. 一种纳米聚集体及其制备方法和应用. 中国发明专利2021109114648.
陆园园, 丁启帆, 江峰等. CPUL1脂质体及其制备方法. 中国发明专利2021104939593.
江峰, 吴仲稀, 王志祥等. 作为TrxR1抑制剂的吩嗪衍生物、中间产物及其制备方法和用途. 中国发明专利2019104264957.
江峰, 闫玉茹, 陆园园等. 一种吡喃并[3,2-a]吩嗪衍生物及其制备方法和用途. 中国发明专利2015108940700.